Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class, potent, orally administered Transient Receptor Potential ...
Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company's migraine drug will "change the paradigm" of migraine prevention and treatment. The U.S. Food and Drug Administration last ...
Biohaven Pharmaceuticals Holding Company Ltd. announced this week it would pay Bristol-Myers Squibb $50 million as part of a deal to restructure its licensing agreement with the pharmaceutical giant ...
Two New Haven-based bioscience firms have announced an agreement to collaborate on research and development of therapies for central nervous system disorders (CNS). Bexorg Inc., a techbio company ...
NEW HAVEN, Conn., Nov. 9, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company"), a biopharmaceutical company with a portfolio of innovative, late-stage product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results